Related references
Note: Only part of the references are listed.Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Elevated Lipoprotein(a) and Risk of Ischemic Stroke
Anne Langsted et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
HEART UK consensus statement on Lipoprotein(a): A call to action
Jaimini Cegla et al.
ATHEROSCLEROSIS (2019)
LP(A) AND CARDIOVASCULAR OUTCOMES: AN ANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL
Vera Bittner et al.
ATHEROSCLEROSIS SUPPLEMENTS (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials
Amirhosssein Sahebkar et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk Assessment The Multi-Ethnic Study of Atherosclerosis
Weihua Guan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Development of Lipoprotein(a) siRNAs for Mechanism of Action Studies in Non-Human Primate Models of Atherosclerosis
Marija Tadin-Strapps et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2015)
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff et al.
CIRCULATION (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Walter N. Kernan et al.
STROKE (2014)
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)
John J. Albers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects The Atherosclerosis Risk in Communities (ARIC) Study
Salim S. Virani et al.
CIRCULATION (2012)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Management of Lp(a)
W. Virgil Brown et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2010)
Apolipoprotein(a) Isoforms and the Risk of Vascular Disease Systematic Review of 40 Studies Involving 58,000 Participants
Sebhat Erqou et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Lipoprotein (a) and stroke - A meta-analysis of observational studies
Barbara Smolders et al.
STROKE (2007)
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease
S Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)